A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Enzastaurin Plus R-CHOP Versus R-CHOP in Treatment-Naive Subjects With High-Risk Diffuse Large B-Cell Lymphoma Who Possess the Novel Genomic Biomarker DGM1™
Phase of Trial: Phase III
Latest Information Update: 26 Nov 2018
At a glance
- Drugs Enzastaurin (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Vincristine
- Indications Diffuse large B cell lymphoma
- Focus Biomarker; Registrational; Therapeutic Use
- Acronyms ENGINE
- Sponsors Denovo Biopharma
- 26 Nov 2018 According to Denovo Biopharma media release, data from this study will be presented at the American Society of Hematology Annual Meeting.
- 03 Apr 2018 According to a Denovo Biopharma media release, first patient has been dosed in this trial.
- 27 Mar 2018 Status changed from not yet recruiting to recruiting.